Congenital Bleeding Disorder — Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Citation(s)
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors